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Method Validation for Preparing Urine Samples for
Downstream Proteomic and Metabolomic Applications
Wim Ammerlaan,1 Jean-Pierre Trezzi,1,2 Conny Mathay,1 Karsten Hiller,2 and Fay Betsou1
Background: Formal validation of methods for biospecimen processing in the context of accreditation in
laboratories and biobanks is lacking. A protocol for processing of a biospecimen (urine) was validated for
fitness-for-purpose in terms of key downstream endpoints.
Methods: Urine processing was optimized for centrifugation conditions on the basis of microparticle counts at
room temperature (RT) and at 4C. The optimal protocol was validated for performance (microparticle counts),
and for reproducibility and robustness for centrifugation temperature (4C vs. RT) and brake speed (soft,
medium, hard). Acceptance criteria were based on microparticle counts, cystatin C and creatinine concentra-
tions, and the metabolomic profile.
Results: The optimal protocol was a 20-min, 12,000 g centrifugation at 4C, and was validated for urine
collection in terms of microparticle counts. All reproducibility acceptance criteria were met. The protocol was
robust for centrifugation at 4C versus RT for all parameters. The protocol was considered robust overall in
terms of brake speeds, although a hard brake gave significantly fewer microparticles than a soft brake.
Conclusions: We validated a urine processing method suitable for downstream proteomic and metabolomic
applications. Temperature and brake speed can influence analytic results, with 4C and high brake speed
considered optimal. Laboratories and biobanks should ensure these conditions are systematically recorded in the
scope of accreditation.
Introduction
B iospecimen processing method validation plays animportant role in the context of quality assurance, ac-
creditation, and biomarker development, and is a normative
requirement for biobank accreditation.1,2 We present here
the second in a series of articles reporting the validation of
methodology for fit-for-purpose biospecimen processing for
downstream applications.3 These articles propose a meth-
odology for formal validation of biospecimen processing,
saving time and resources to establish the conditions.
Validation is based on reproducibility, robustness, and
sample stability.
A large array of proteins are present in urine, reflecting the
physiology of the kidneys, urogenital tract, and blood, making
urine evaluation an integral part of clinical care and biomarker
research. Urine is proving to be an increasingly useful source of
metabolites and protein biomarkers for detecting disease states
in both adults and neonates,4–7 as well as the effects of drugs and
dietary intake on physiologic processes.8–10 Best Practices11
and Standard Operating Procedures12–16 for routine processing
and storing of biobank samples have been published.
Pellets resulting from centrifugation of urine contain cells,
cell debris, sometimes bacteria, and nucleic acids (both human
and microbial) that can be used for genetic analyses and di-
agnoses.17,18 Microparticles and exosomes, small membrane
vesicles originating as membrane or internal vesicles, respec-
tively, are secreted into the urine from nephron segments. They
contain proteins, lipids, and RNA. Their protein profile may be
altered in a variety of disease states, and as such can be used as a
source of biomarkers.19 Exosomes (10–100nm) represent an
important source of low abundance protein biomarkers and
they are isolated from urine supernatant via ultracentrifugation.
Indeed, the Urinary Exosomes Protein Database (http://dir
.nhlbi.nih.gov/papers/lkem/exosome/) containsmore than 1200
protein sequences. Small particles in the range of 500 nm-3mm
may contain bacteria, cell debris, and apoptotic bodies. High
and unreproduciblemicroparticle concentrationsmay affect the
accuracy of proteomic applications and protein assays,20 in
either the exosome-associated or exosome-independent pro-
teome, underlining the importance of having urine samples that
are relatively free of microparticles for use in biomarkers. Our
objective was to obtain a urine sample as ‘‘clean’’ as possible
from sedimenting small particles (which represent 48% of total
protein in urine), but still containing the exosomal component
(which accounts for 3% of total protein in urine).21 Applica-
tions based on protein and nucleic acid contents of exosomes
and microparticles are not in the scope of this work.
1Integrated BioBank of Luxemburg (IBBL), Luxembourg.
2Luxembourg Centre for Systems Biomedicine (LCSB), Luxembourg.
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The levels of creatinine (a byproduct of muscle metabolism)
andcystatinC (abiomarker for glomerularfiltration rate) inurine
are well correlated except in individuals with renal tubular
damage.22 Creatinine and cystatin C levels are considered a
proxy for total protein concentration and they are used for cat-
egorization of urine samples for proteomics analyses, and are
thus considered markers for reproducibility and robustness.
In this article, we report a methodology, including an
optimization step, for preparing cell-free and debris-free
urine supernatant samples. The optimal methodology was
validated in terms of reproducibility and robustness, with a
fit-for-purpose approach for urine preparation.
Materials and Methods
Study design
Initially, three centrifugation speeds were evaluated at
room temperature (RT, 19–24C) to assess elimination of
microparticles by sedimentation. However, given that pro-
cessing samples at 4C minimizes degradation and possible
microbial growth, centrifugation was also performed under
refrigerated conditions. Optimization was determined on the
basis of microparticle counts. The optimal protocol was then
validated for robustness (brake speed and centrifugation
temperature) and reproducibility in terms of microparticle
counts, cystatin C, and creatinine concentrations, and me-
tabolomic output. The workflow is shown in Table 1. The
study was performed in accordance with the Declaration of
Helsinki (1975, revised in 2008). Urine samples were col-
lected from healthy volunteers who provided written in-
formed consent (CNER approval ##201107/02).
Urine collection protocols
Mid-stream urine samples (100mL) were collected from two
healthy volunteers (onemale and one female, aged 35–50 years)
in 125mL sterile polypropylene urine collection cups (VWR,
#216-2659). Samples (20mL for optimization, 25mL for all
other protocols) were transferred to 50-mL, high-performance
conical tubes (VWR #525-0158) and centrifuged in a 5810R
Eppendorf centrifuge or a ThermoScientific SL40 FR centrifuge
at 4C within 3 hours of collection. For double centrifuga-
tion, supernatant (13mL) was transferred to 15-mL high-
performance conical tubes (VWR #252-0163). Supernatant
(10mL) was collected after single or double centrifugation.
Samples formicroparticle countingwere processed immediately
and the remainder transferred to 15-mL high-performance
Table 1. Plan of Urine Aliquoting Method Optimization and Validation
Optimization 1 Optimization 2
Robustness
(Deceleration)
Robustness
(Temperature) Reproducibility
Donor
 quantity one two one one one
 volume 150mL 100mL 100mL 100mL 100mL
Centrifugation
 speed (D) 2000–4000 g (D) 2000–12000 g 12000 g 12000 g 12000 g
(D) 2000–10000 g (S) 12000 g
(D)2000–120000 g
(S1) 1000 g
(S2) 2000 g
(S3) 10000 g
 time (D) 10–10min (D) 10-10min 20min 20min 20min
(S1–S2) 10min (S) 20min
(S3)20min
 temperature RT 4C 4C 4C 4C
RT
 brake speed (D) med- hard (D) med-hard soft hard hard
(S) med (S) med med
hard
Transfer and mix 10mL 10mL 10mL 10mL 10mL
 aliquoting 10 · 1.0mL 10 · 1.0mL 10 · 1.0mL 10 · 1.0mL 10 · 1.0mL
Microparticles
 test frequency triplicate triplicate triplicate triplicate triplicate
 volume/test 100mL 100mL 100mL 100 mL 100mL
Cystatin C
 test frequency n.d. n.d. duplicate duplicate duplicate
 volume/test 50mL 50 mL 50mL
Creatinine
 test frequency n.d. n.d. duplicate duplicate duplicate
 volume/test 10mL 10 mL 10mL
Metabolomics
 test frequency n.d. n.d. triplicate triplicate triplicate
 pre-treatment 100mL 100 mL 100mL
 volume/test 5mL 5 mL 5mL
n.d., not determined; (S), single centrifugation; (D), Double centrifugation.
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conical tubes, inverted five times. One-mL aliquots in 2-mL
polypropylene tubes were prepared and stored at - 80C for
analysis of cystatin C and creatinine concentrations, and meta-
bolomics. Samples evaluated at 4Cwere kept on ice throughout
processing.
Centrifugation conditions
For optimization, three centrifugation speeds were eval-
uated at RT (one donor, one sample per protocol): 1000 g
and 2000 g (both 10min with medium brake) and 10,000 g
(20min with hard brake). In a second step, centrifugation
was evaluated at 4C (two donors, one sample split between
protocols), comparing a single centrifugation (12,000 g,
20min with medium brake) with a double centrifugation
(2000 g, 10min with medium brake, then 12,000 g, 10min
with hard brake). Robustness/brake speeds (one donor, one
sample split into three) conditions were soft brake versus
medium brake and hard brake, at 4C, 12,000 g, 20min.
Robustness/temperature (one donor, one sample split into
two) were 4C versus 21C, at 12,000 g, 20min, hard brake.
Reproducibility (one donor, one sample split into three)
conditions were 12,000 g, 4C, 20min, hard brake.
Microparticle counting
Microparticles were counted using a CASY TTC
Measuring and Monitoring Device (Roche Applied Sci-
ence) equipped with a 45 mm aperture capillary, and
CASY Measure v1.7 software, using an in-house small-
particle setup. Urine supernatant samples (100 mL) at RT
were added to 10mL CASY-ton solution. For optimization,
three 200 mL sample uptakes were evaluated, plotting
counts on a 10-mm scale. For validation, a single 200 mL
uptake and a 5-mm scale were used. Events in the range of
0.67–3.00 mm were considered microparticles. Counts were
performed in triplicate.
Creatinine and cystatin C quantification
Creatinine concentrations were determined using the
Creatinine Parameter Assay Kit (R&D Systems) and cy-
statin C with the Human Cystatin C Quantikine ELISA Kit
(R&D Systems), according to the manufacturer’s instruc-
tions. Briefly, urine supernatant for creatinine analysis was
diluted 20-fold and treated with alkaline picrate solution
( Jaffe reaction) for 30min on a microtiter plate. For cystatin
C detection, urine supernatant was used undiluted in a
sandwich ELISA in a microtiter plate. Primary incubation
was performed at 2–8C for 3 hours, plates were then
washed, followed by a 1-hour incubation with cystatin C
conjugate at 2–8C. After washing, samples were incubated
for 30min with substrate solution at RT. Absorption was
measured at 490 nm for creatinine and 450 nm for cystatin C
using a Synergy spectrophotometer (Biotek) and test sam-
ples were compared with standard ranges. Both assays were
run in duplicate on a single plate.
Metabolite extraction
Urine supernatant (100 mL) was mixed with 75 mL urease
(5mg/mL, Sigma-Aldrich) and incubated for 5min at 37C
with 400 rpm shaking. A 5-mL sample of processed urine
was mixed with 45 mL methanol/water (8:1), placed on a
shaking device (5min, 4C) then immediately centrifuged at
16,000 g (5min, 4C) in a 5415R centrifuge (Eppendorf).
Supernatant (30 mL) was transferred to gas chromatography
glass vials and completely dried ( - 4C, 40min) with a
refrigerated CentriVap Concentrator (Labconco). To avoid
condensation, the Concentrator was heated to RT for 15min
prior to vial removal. Metabolite extraction was performed
in triplicate for each sample.
Metabolomics GC-MS analysis
GC-MS measurements were performed on an Agilent 6890
gas chromatograph equipped with a DB-35MS capillary col-
umn. The chromatograph was coupled to an Agilent 5975C
mass spectrometer equipped with an electron impact ioniza-
tion source operating at 70 eV. The spectrometer source was
heated to 230C and the quadrupole to 150C. Online me-
tabolite derivatization was performed with a Multipurpose
Sampler (Gerstel). Dried metabolite extracts were mixed with
15mL 2% methoxyamine hydrochloride in pyridine (MOX;
Thermo Fisher) and incubated for 30min at 40C, then in
15mL 2,2,2-trifluoro-N-methyl-N-trimethylsilyl-acetamide
Table 2. Optimization of Urine Centrifugation Protocol, According to Microparticle Counts
Microparticle Countsa (counts/mL)
Centrifugation Protocol Count 1 Count 2 Count 3 Mean (SD) p-valueb
Room temperature
1000 g, medium brake, 10min 9.74 · 106 8.69· 106 9.51 · 106 9.31 · 106 (0.55· 106) < 0.001
2000 g, medium brake, 10min 7.10 · 106 6.97· 106 7.73 · 106 7.27 · 106 (0.41· 106
10,000 g, hard brake, 20min 4.67 · 106 4.46· 106 4.64 · 106 4.59 · 106 (0.11· 106)
4C, Donor 1
12,000 g, medium brake, 20min 1.36 · 106 1.42· 106 1.55 · 106 1.44 · 106 (0.10· 106) 0.014
2000 g, medium brake + 12000 g, hard brake
(both 10min)
2.86 · 106 2.85· 106 3.61 · 106 3.11 · 106 (0.44· 106)
4C, Donor 2
12,000 g, medium brake, 20min 4.89 · 105 6.14· 105 9.17 · 105 6.73 · 105 (2.20· 105) 0.003
2000 g, medium brake + 12000 g, hard brake
(both 10min)
1.39 · 106 1.61· 106 2.02 · 106 1.68 · 106 (0.32· 106)
aRT: one donor sample; 4C, two donors; triplicate counts for each protocol; bOne-way Anova test.
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(MSTFA; Machery Nagel) for 30min at 40C. The detector
was operated in scan mode and the sampler injected 1mL of
derivatized sample. The injection was set to splitless mode
with helium as the carrier gas (1mL/min flow rate). The gas
chromatography oven was maintained at 80C for 6min, then
increased to 300C (by 6C/min), then to 325C (by 10C/
min), and maintained for 4min. GC-MS raw data was pro-
cessed using the MetaboliteDetector software23 with retention
index calibration enabled. Settings were: minimum number of
ions= 10; minimum peak height= 5 noise levels; deconvolu-
tion width= 5 scans. Samples were analyzed in triplicate. For
each replicate, individual metabolite intensity was divided by
the sum of all peak intensities from the sample.
Validation criteria
Robustness was evaluated in terms of brake speed (soft,
medium, hard) and temperature (4C versus RT). Accep-
tance criteria were: 1) microparticle counts < 1 · 107/mL,
based on previously measured ranges of urine microparticle
concentrations (Ammerlaan, unpublished data); 2) cystatin
C concentration 6–100 ng/mL, corresponding to reference
ranges of cystatin C in healthy subjects;22 3) creatinine
concentration in the undiluted samples, 12–200mg/dL,
corresponding to reference ranges of creatinine in healthy
subjects;22 4) nonsignificant differences in mean micropar-
ticle counts, and creatinine and cystatin C concentrations;
and 5) a nonsignificant difference in concentrations of
> 95% of detected metabolites between different conditions.
Reproducibility acceptance criteria were: 1) microparticle
counts < 1 · 107/mL; 2) cystatin C concentration 6–100 ng/
mL; 3) creatinine concentration 12–200mg/dL; 4) CV (co-
efficient of variation) < 20% for mean microparticle counts,
and creatinine and cystatin C concentrations; and 5) a
nonsignificant difference in concentrations of detected me-
tabolites of > 95% between replicates from a given donor.
Statistical analyses
Mean, SD, and CV were calculated using Excel. Micro-
particle counts, and creatinine and cystatin C concentrations
were compared between protocols (optimization), conditions
(robustness), or replicates (reproducibility) using one-way
Anova tests or paired two-tailed t-tests. Pairwise multiple
comparisons (Holm-Sidak) were performed if a significant
difference was detected. For metabolomics, semi-quantitative
data were obtained with batch quantification (nontargeted
analysis) and statistically tested by one-way Anova and
Welch’s t-test. Significance was calculated with Sigma Plot
v.12.0 (Systat Software) and R.3.0.0, with a 5% significance
threshold.
Table 4. Robustness, According to Centrifugation Temperature
Mean (SD)b
Evaluation parametera
(acceptance criteria) 4C 21C
p-valuec/% NS diff.
metabolite conc.
Test power
(l= 0.05) Outcomed
Microparticle counts/mL
( < 1 · 107/mL)
7.56 · 106 (6.27 · 106) 4.50 · 106 (1.85 · 106) p = 0.383 0.068 Accepted
Cystatin C conc., ng/mL
(6–100 ng/mL)
23.7 (0.48) 22.5 (1.36) p = 0.546 0.093 Accepted
Creatinine conc., mg/dL
(12–200mg/dL)
52.1 (2.3) 47.3 (0.3) p = 0.184 0.212 Accepted
% NS diff. metabolite
conc. ( > 95%)
99.4% Accepted
CV, coefficient of variation; NS, nonsignificant.
aUrine collection protocol: 12,000 g, 20min,hard brake; bOne donor sample measured in triplicate for microparticle counts and duplicate
for cystatin C and creatinine; cVariation (paired t-test) between temperatures for microparticles, cystatin C and creatinine concentrations;
dBased on values within acceptance criteria, NS differences between temperatures for microparticle counts, cystatin C and creatinine
concentrations, and in concentrations of > 95% metabolites (one-way Anova).
Table 3. Robustness, According to Centrifugation Deceleration
Mean (SD)b
Evaluation parametera
(acceptance criteria)
Soft brake
(low)
Medium brake
(moderate)
Hard brake
(fast)
p-valuec/%
NS diff.
metabolite
conc. Outcomed
Microparticle counts/mL
( < 1 · 107/mL)
6.46 · 106 (1.98 · 106) 3.93 · 106 (1.21 · 106) 2.12 · 106 (0.70 · 106) p = 0.025 Rejected
Cystatin C conc., ng/mL
(6–100 ng/mL)
26.6 (3.5) 27.4 (4.7) 27.1 (1.3) p = 0.976 Accepted
Creatinine conc., mg/dL
(12–200mg/dL)
70.2 (0.4) 69.4 (0.3) 67.4 (1.3) p = 0.078 Accepted
% NS diff. metabolite
conc. ( > 95%)
97.0% Accepted
CV, coefficient of variation; NS, nonsignificant.
aUrine collection protocol: 12,000 g, 20min, 4C; bOne donor sample measured in triplicate for microparticle counts and duplicate for
cystatin C and creatinine; cVariation (one-way Anova) between brake speeds for microparticles, cystatin C and creatinine concentrations.
dBased on values within acceptance criteria, NS differences between brake speeds for microparticle counts, cystatin C and creatinine
concentrations, and in concentrations of > 95% metabolites (one-way Anova).
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Results
Optimization of urine processing protocol
Microparticle counts were determined for three centrifu-
gation protocols at RT (Table 2). Significant differences in
microparticle counts were reported between the three pro-
tocols ( p < 0.001) in Anova one-way tests and between all
combinations in pairwise multiple comparisons, with higher
centrifugation speeds giving lower microparticle counts. At
4C, a single centrifugation of 20min at 12,000 g, medium
brake resulted in significantly lower microparticle counts
compared to the double centrifugation (2000 g, medium
brake, followed by 12,000 g, hard brake; 10min each), in
both donors (Table 2).
Validation of urine processing protocol
Robustness
Centrifugation deceleration. Following optimization,
which showed a single centrifugation of 20min at 12,000 g,
medium brake to be optimal, robustness was evaluated in
terms of the effect of different brake speeds on centrifuga-
tion at 4C. Urine samples had significantly different mi-
croparticle counts with the three brake speeds, the number
of microparticles decreasing with increasing brake speed,
and microparticle-associated acceptance criteria were not
met (Table 3). A pairwise multiple comparison showed the
significant difference to be only between the highest and
lowest brake speeds. The protocol was robust for different
brake speeds for all other parameters, each of which was
within the acceptance criteria limits, and was without
significant differences for cystatin C and creatinine con-
centrations; 10 out of 331 detected metabolites were sig-
nificantly different, giving a 97% rate of metabolites with
nonsignificant differences. One of the significantly affected
metabolites could be identified as glycine. With the hard
brake giving lower microparticle counts (albeit not statisti-
cally significant compared to the medium brake), the hard
brake was selected for the optimized protocol as it allows
quicker processing times.
Centrifugation temperature. Robustness was also evalu-
ated in terms of the effect of centrifugation at 4C versus
21C. The protocol proved to be robust for all parameters,
being within the acceptance criteria limits and without sig-
nificant differences for microparticle counts, and cystatin C
and creatinine concentrations, while two out of 310 detected
metabolites were significantly different, giving a 99.4% rate
of nonsignificant difference (Table 4).
Reproducibility
The methodology acceptance criteria in terms of micro-
particle counts were met for all three replicates in the repro-
ducibility assessment (Table 5). Reproducibility acceptance
criteria were met for all parameters; microparticle counts,
cystatin C and creatinine concentrations limits, CV < 20%,
and nonsignificant differences in concentrations of > 95% of
metabolites (Table 5). The protocol yielded 14 out of 413
detected metabolites (3.4%), which were significantly differ-
ent (metabolite results are available on request). The 20-min,
12,000 g centrifugation at 4C with hard brake was validated
as reproducible for urine collection.
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Discussion
The uncontrolled presence of microparticles in the context
of identifying biomarkers is a potential confounder, and low
microparticle counts are considered optimal. With our initial
analyses showing that higher centrifugation speeds result in
lower microparticle counts at RT, centrifugation at 4C was
performed at 12,000 g, with the single centrifugation taking
preference over the double in light of significantly lower mi-
croparticle counts.While two-step centrifugation is optimal for
intact cell isolation (in the pellet of the first centrifugation),
a single high-speed centrifugation gives lower microparticle
counts, is more amenable to automation, is less time consum-
ing, and is less sensitive to handling errors, making it the
method of choice for urine processing when the intact cell
fraction is not of interest for downstream use.
The method was robust overall for different brake speeds,
although significantly lower microparticle counts were ob-
tained with a hard brake, reflecting the fact that weaker
braking and longer deceleration times favor significant re-
lease of microparticles into the supernatant. This suggests that
a hard brake is optimal and highlights the importance of
systematically reporting the brake speed. The protocol proved
robust when comparing centrifugation at 4C versus RT, with
all acceptance criteria met. The 20-min centrifugation at
12,000 g at 4C with hard brake was reproducible in terms of
mean microparticle counts, cystatin C and creatinine con-
centrations within acceptable limits, with a CV less than 20%,
and a profile of metabolites with > 95% without significant
differences. Where proteomic and metabolomic research is
concerned, pre-processing and processing of samples at 4C
is considered essential. Not only does it minimize protein
degradation due to protease activity,24–26 it also limits me-
tabolite changes that can occur due to bacterial growth at
RT,27 and potential microbial growth due to the nonsterile
nature of urine.28 Glycine could be unambiguously identified
and was found to be poorly reproducible.
Neither protease inhibitors nor other stabilizers were used
in this protocol. It has been shown that polypropylene tubes
without any preservative can be used for multipotency urine
test strip analyses and particle counting when kept at
4C.29,30 It has also been shown that urinary proteins un-
dergo rapid degradation when left at RT, regardless of the
presence of protease inhibitors which only have a protective
effect within 2 hours of collection.31
Varying susceptibility of a range of urinary proteins to
degradation under different storage conditions has been re-
ported. Creatinine is stable for up to 2 years when stored at
- 20C or - 80C, while at 4C it is stable for 30 days.32
Cystatin C is stable for 7 days at both 4C and - 20C and
for 48 h at 20C, for up to three freeze/thaw cycles and at
pH > 5.33 It has recently been shown that post-centrifugation
delays of up to 48 hours at either RT or 4C do not have a
significant impact on the levels of biomarkers of acute
kidney injury (neutrophil gelatinase-associated lipocalin,
interleukin-18, kidney injury molecule 1, liver-type fatty
acid-binding protein).34 In order to prevent degradation of
more sensitive molecules, a post-centrifugation delay of less
than 2 hours at 4C, storage of urine supernatant at - 80C,
and avoiding freeze/thaw cycles is recommended.
We provide here formal validation of the methodology for
a urine processing protocol of a 20-min centrifugation at
12,000 g at 4C using a hard brake that is fit-for-purpose for
the use of urine supernatant in proteomic and metabolomic
analyses (Table 6). Because of the small number of samples
used in our study, the power is limited and negative results
should be interpreted with caution. The pellet can be used
for DNA-based analyses such as genotyping35 or urinary
metagenomics analyses.28 Microparticles in the supernatant
can be isolated for further analyses by ultracentrifugation at
a later stage, after storage at - 80C.21,36
Urine preanalytical conditions have been studied in specific
proteomic methods including MALDI-TOF-MS,37 2D-elec-
trophoresis,4 SELDITOF MS,31 and LC-MS,38 showing that
collection and processing variables can have a major impact on
specific proteins and peptides. In this context, laboratories and
biobanks operating under accreditation are advised to track and
record preanalytical data systematically using the Standard
PREanalytical Code (SPREC),39,40 while freeze-thaw cycles
and other treatments (e.g., use of protease inhibitors, stabiliz-
ers) should be reported in the Laboratory Information Man-
agement System. Biobanks and clinical laboratories facing
accreditation requirements and/or processing biospecimens for
clinical biomarker research can implement the urine prepara-
tion methods presented here with reference to this publication.
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